Kezar Life Sciences, Inc.
NASDAQ:KZR
7.09 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|
Omzet
| 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Kosten van de omzet
| 1.066 | 1.023 | 1.51 | 1.544 | 1.301 | 0.69 | 0.175 | 0.154 |
Brutowinst
| 5.934 | -1.023 | -1.51 | -1.544 | -1.301 | -0.69 | -0.175 | -0.154 |
Brutowinstmarge
| 0.848 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Onderzoek- en ontwikkelingskosten
| 85.697 | 51.009 | 38.935 | 30.981 | 27.363 | 18.136 | 6.469 | 7.373 |
Algemene en administratieve kosten
| 26.54 | 20.153 | 15.724 | 11.969 | 9.979 | 6.59 | 2.28 | 1.617 |
Verkoop- en marketingkosten
| -1.066 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Verkoop-, algemene en administratieve kosten
| 25.474 | 20.153 | 15.724 | 11.969 | 9.979 | 6.59 | 2.28 | 1.617 |
Overige kosten
| 6.187 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bedrijfskosten
| 111.171 | 71.162 | 54.659 | 42.95 | 37.342 | 24.726 | 8.749 | 8.99 |
Bedrijfsresultaat
| -105.237 | -71.162 | -54.659 | -42.95 | -37.342 | -24.726 | -8.749 | -8.99 |
Bedrijfsresultaat ratio
| -15.034 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totaal overige inkomsten en kosten netto
| 3.367 | 2.923 | 0.029 | 1.208 | 2.255 | 1.559 | 0.232 | 0 |
Inkomen voor belasting
| -101.87 | -68.239 | -54.63 | -41.742 | -35.087 | -23.167 | -8.517 | -8.99 |
Inkomen voor belasting ratio
| -14.553 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Belastingkosten
| 0.898 | -2.923 | -1.351 | -2.752 | -3.556 | 1.559 | 0 | 0 |
Nettowinst
| -101.87 | -65.316 | -53.279 | -38.99 | -31.531 | -23.167 | -8.517 | -8.99 |
Nettowinstmarge
| -14.553 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WPA (Winst Per Aandeel)
| -1.4 | -0.97 | -1.01 | -0.89 | -1.65 | -2.26 | -0.65 | -0.69 |
Verwaterde WPA
| -1.4 | -0.97 | -1.01 | -0.89 | -1.65 | -2.26 | -0.65 | -0.69 |
EBITDA
| -104.171 | -71.162 | -54.471 | -42.95 | -37.342 | -24.726 | -8.574 | -8.836 |
EBITDA ratio
| -14.882 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |